September 17, 2013
Pfizer Japan announced on September 13 that its anticancer agent Xalkori (crizotinib）significantly extended progression-free survival (PFS), in comparison with standard chemotherapy, in patients with anaplastic lymphoma kinase (ALK) fusion gene-positive advanced non-small cell lung cancer (NSCLC) who had a previous...read more